ASCO 23 (American Society of Clinical Oncology) Annual Meeting in Chicago showcased a plethora of cutting-edge trials and research. Upper gastrointestinal cancers such as gastric, pancreatic and hepatobiliary are usually relegated to the backstage, but this year, several exciting and potentially practice-changing studies (not without their limitations).

We explore a new PD-1Toripalimab in gastric and gastroesophageal cancer, liposomal irinotecan in NALIRIFOX versus gemcitabine/abraxane in metastatic pancreatic cancer, neoadjuvant FOLFIRINOX in pancreatic cancer and the new HER2 kid on the block zanidatamab, a bispecific monoclonal antibody.

Stay tuned for daily ASCO updates from the OFTIM team, Michael and Josh.

Studies:

Toripalimab + SOX study: https://meetings.asco.org/abstracts-presentations/219777

NAPOLI-3 study: https://meetings.asco.org/abstracts-presentations/222090

NORPACT-1 study: https://meetings.asco.org/abstracts-presentations/219426

HORIZON-BTC-01 study: https://meetings.asco.org/abstracts-presentations/219904

Special Mention (not included in the episode)

DIPLOMA Study: https://meetings.asco.org/abstracts-presentations/218312

Lauren Classification: https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodes

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.